Rapid and massive expansion of cord blood-derived cytokine-induced killer cells: an innovative proposal for the treatment of leukemia relapse after cord blood transplantation.

Abstract:

:We have used a standardized 21-day expansion protocol to produce cytokine-induced killer (CIK) cells starting from very small amounts of nucleated cells (approximately 15 x 10(6) cells) isolated from cord blood. Mononuclear cells are stimulated with anti CD3 (OKT3) and IFNgamma and then expanded with IL-2. Moreover, we show that washouts of cord blood units bags (at the end of the infusion) may be sufficient to yield almost 500 x 10(6) CIK by the same expansion protocol. CIK cells show strong cytotoxic activity against a variety of tumor target cell lines including B and T lymphomas and myeloid leukemias. More importantly, expanded cord blood-derived CIK cells are cytotoxic against fresh leukemic blasts and express perforin, granzyme and NKG2D molecule at high levels. The same in vitro protocol has already been used to expand CIK cells from peripheral blood of adult donors under GMP conditions and therefore these observations open up the possibility of imagining a future clinical application of leukemia relapse following cord blood transplantation with CIK cells obtained from the same cord blood unit.

journal_name

Bone Marrow Transplant

authors

Introna M,Franceschetti M,Ciocca A,Borleri G,Conti E,Golay J,Rambaldi A

doi

10.1038/sj.bmt.1705503

subject

Has Abstract

pub_date

2006-11-01 00:00:00

pages

621-7

issue

9

eissn

0268-3369

issn

1476-5365

pii

1705503

journal_volume

38

pub_type

杂志文章
  • Hematopoietic stem cell transplantation for adults with acute promyelocytic leukemia in the ATRA era: a survey of the European Cooperative Group for Blood and Marrow Transplantation.

    abstract::We performed a survey of the European Cooperative Group for Blood and Marrow Transplantation to analyze the outcome of 625 acute promyelocytic leukemia (APL) patients transplanted with auto- or allogeneic-hematopoietic stem cell transplantation (autoHSCT, alloHSCT) after 1993, in first (CR1) or in second complete remi...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,多中心研究

    doi:10.1038/sj.bmt.1705620

    authors: Sanz MA,Labopin M,Gorin NC,de la Rubia J,Arcese W,Meloni G,Bacigalupo A,Alessandrino P,Carreras E,Iriondo A,Novitzky N,Jacobs P,Bandini G,Lo-Coco F,Frassoni F,Rocha V,Acute Leukemia Working Party (ALWP) of European Cooper

    更新日期:2007-04-01 00:00:00

  • New strategies in GVHD prophylaxis.

    abstract::Despite immunosuppressive therapy using cyclosporine (CsA) and prednisolone and methotrexate (MTX), the incidence for aGVHD grade II to IV after transplantation from HLA matched unrelated donors (MUD) is 78%, the incidence for grade III and IV 36%. Since GVHD contributes to morbidity and mortality after MUD-BMT, a mor...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702346

    authors: Kiehl MG,Shipkova M,Basara N,Blau WI,Fauser AA

    更新日期:2000-05-01 00:00:00

  • HLA-DP and allogeneic bone marrow transplantation.

    abstract::HLA-DP typing is not routinely performed before allogeneic BMT. This highly polymorphic class II locus is implicated in immune response and DP molecules may act as transplantation antigens. HLA-DP incompatibilities contribute to MCL. In BMT performed between siblings, HLA-DP mismatches are rare and the role of such in...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Moreau P,Cesbron A

    更新日期:1994-06-01 00:00:00

  • Risk of relapse in patients receiving azithromycin after allogeneic HSCT.

    abstract::Following publication of the ALLOZITHRO trial, the FDA released a safety announcement warning that azithromycin should not be given long-term to prevent BOS in patients with a blood or lymph cancer who have undergone allogeneic HSCT. Our site typically initiated azithromycin when patients were diagnosed with BOS post-...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-020-01095-8

    authors: Kutzke JL,Merten JA,Taraba JL,Mara KC,Shah MV,Hashmi SK,Patnaik MM,Litzow MR,Hogan WJ,Alkhateeb HB

    更新日期:2020-10-31 00:00:00

  • Turkish Transplant Registry: a comparative analysis of national activity with the EBMT European Activity Survey.

    abstract::SCT is a curative approach using chemo-, radio- and immunotherapy for malignant and non-malignant hematological disorders. The European Group for Blood and Marrow Transplantation (EBMT) has been collecting yearly data on a survey basis since 1990. The variables within the survey are limited to detailed indications, nu...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2008.144

    authors: Arat M,Arpaci F,Ertem M,Gürman G,Turkish Transplant Registry.

    更新日期:2008-08-01 00:00:00

  • Early cyclosporine taper in high-risk sibling allogeneic bone marrow transplants.

    abstract::Graft-versus-tumour reactions as a form of adoptive immunotherapy may help prevent the recurrence of haematological malignancy following allogeneic BMT. We hypothesised that such reactions may be maximised by shortening the duration of post-transplant immunosuppression by a rapid taper of cyclosporine (CYA). CYA dose ...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1700961

    authors: Abraham R,Szer J,Bardy P,Grigg A

    更新日期:1997-11-01 00:00:00

  • Hematopoietic cell transplantation for thalassemia and sickle cell disease: past, present and future.

    abstract::beta-Thalassemia major and sickle cell disease (SCD) are among the most common hereditary disorders worldwide. The supportive treatment of beta-thalassemia major requires chronic, life-long RBC transfusions, which cause progressive iron overload and the potential for impaired endocrine, cardiac and hepatic function. T...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705943

    authors: Bhatia M,Walters MC

    更新日期:2008-01-01 00:00:00

  • Evaluation of uroprotective efficacy of amifostine against cyclophosphamide induced hemorrhagic cystitis.

    abstract::The role of amifostine in the prevention of cyclophosphamide-induced hemorrhagic cystitis (HC) was evaluated in the rat model. Urinary bladders from control rats that received no drugs (group I) were compared with those from rats receiving cyclophosphamide alone at a dose of 150 mg/kg (group II), and two other groups ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701598

    authors: Srivastava A,Nair SC,Srivastava VM,Balamurugan AN,Jeyaseelan L,Chandy M,Gunasekaran S

    更新日期:1999-03-01 00:00:00

  • Does haploidentical transplantation in children with primary immunodeficiencies have the potential to exploit donor NK cell alloreactivity?

    abstract::Donor potential to exert NK cell alloreactivity has been shown to confer survival advantage in haploidentical hematopoietic cell transplantation for hematological malignancies. We investigated killer immunoglobulin receptor (KIR) ligand incompatibility in 40 children receiving haploidentical transplantation for primar...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1704663

    authors: Dal-Cortivo L,Ouachée-Chardin M,Hirsch I,Blanche S,Fischer A,Cavazzana-Calvo M,Caillat-Zucman S

    更新日期:2004-12-01 00:00:00

  • Characterization of chemotherapy mobilized peripheral blood progenitor cells for use in autologous stem cell transplantation.

    abstract::Twenty patients were treated with chemotherapy to mobilize progenitors into the blood. Peripheral blood stem cells were quantitated in peripheral blood or leukapheresis products using colony assays and flow cytometric measurement of CD34+ cells. In four patients where complete sets of serial samples were obtained, the...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Bender JG,Williams SF,Myers S,Nottleman D,Lee WJ,Unverzagt KL,Walker D,To LB,Van Epps DE

    更新日期:1992-09-01 00:00:00

  • Use of an immunoglobulin preparation enriched for IgM (Pentaglobin) for the treatment of acute graft-versus-host disease.

    abstract::Pentaglobin is a commercial immunoglobulin preparation which is enriched specifically for IgM and also contains antibodies that are capable of neutralizing endotoxins. Its potential use in treating patients with acute graft-versus-host disease (GVHD) was studied in a phase I/II study. Pentaglobin was administered at a...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Klingemann HG,Barnett MJ,Reece DE,Shepherd JD,Phillips GL

    更新日期:1990-09-01 00:00:00

  • Role of marrow microenvironment in engraftment and maintenance of allogeneic hematopoietic stem cells.

    abstract::Following allogeneic marrow transplantation a competent marrow microenvironment consists of a complex mixture of both donor and host derived cells. Clearly some forms of genetic disparity between donor and host can compromise appropriate interactions and function of these cells. The competency of the microenvironment ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:

    authors: Torok-Storb B,Holmberg L

    更新日期:1994-01-01 00:00:00

  • Prophylaxis and treatment of GVHD after allogeneic haematopoietic SCT: a survey of centre strategies by the European Group for Blood and Marrow Transplantation.

    abstract::Recommendations on indications for allogeneic haematopoietic SCT have been presented, but transplantation techniques remain poorly standardized. Pre-transplant risk factors are well defined, and reported outcomes vary markedly among patients with similar risk characteristics. It would be of importance to know the impa...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2012.45

    authors: Ruutu T,van Biezen A,Hertenstein B,Henseler A,Garderet L,Passweg J,Mohty M,Sureda A,Niederwieser D,Gratwohl A,de Witte T

    更新日期:2012-11-01 00:00:00

  • Patients with acute myeloid leukemia undergoing allogeneic hematopoietic cell transplantation: trends in survival during the past two decades.

    abstract::It remains unclear how specific innovations in allogeneic hematopoietic cell transplantation (HCT) attained over the past decades have contributed to improvement in transplantation outcomes. To address this question, we conducted a registry-based study of adults with acute myeloid leukemia in first or second complete ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-018-0301-7

    authors: Yanada M,Masuko M,Mori J,Aoki J,Mizuno S,Fukuda T,Kakihana K,Ozawa Y,Ota S,Kanamori H,Mori T,Nakamae H,Eto T,Shiratori S,Maeda T,Iwato K,Ichinohe T,Kanda Y,Tanaka J,Atsuta Y,Yano S

    更新日期:2019-04-01 00:00:00

  • Complete heart block in association with graft-versus-host disease.

    abstract::An infant who received haploidentical BM for severe combined immunodeficiency (SCID) developed acute, reversible complete heart block in association with an exacerbation of GVHD. Respiratory distress and myocardial dysfunction were also seen with this and previous GVHD exacerbations. The patient had not received chemo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701038

    authors: Gilman AL,Kooy NW,Atkins DL,Ballas Z,Rumelhart S,Holida M,Lee N,Goldman F

    更新日期:1998-01-01 00:00:00

  • Double high-dose chemoradiotherapy with autologous stem cell transplantation can induce molecular remissions in multiple myeloma.

    abstract::Fifteen patients with stage II-III multiple myeloma were intended to undergo two sequential cycles of myeloablative chemoradiotherapy with autologous bone marrow or blood stem cell transplantation after response to primary induction chemotherapy. BM grafts were used in 13 of the 15 first transplants whereas PBSC were ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Björkstrand B,Ljungman P,Bird JM,Samson D,Gahrton G

    更新日期:1995-03-01 00:00:00

  • Allogeneic hematopoietic cell transplantation outcomes for children with B-precursor acute lymphoblastic leukemia and early or late BM relapse.

    abstract::Large registry studies have shown superior disease-free survival (DFS) with matched sibling donor (MSD) allogeneic hematopoietic cell transplantation (allo-HCT) over chemotherapy alone for patients with B-precursor acute lymphoblastic leukemia (ALL) and a late BM relapse. As most of these patients will not have an MSD...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2010.217

    authors: Beck JC,Cao Q,Trotz B,Smith AR,Weigel BJ,Verneris MR,Burke MJ

    更新日期:2011-07-01 00:00:00

  • Long-term results of autologous marrow transplantation for relapsed or refractory male or female germ cell tumors.

    abstract::Twenty-one patients with relapsed or refractory germ cell tumors were treated with high-dose chemotherapy and marrow transplantation (HDC/BMT) from 1982-1993. Primary sites of disease were testis (17), ovary (three), and pineal gland (one). Pathology included dysgerminoma (one), choriocarcinoma with adenocarcinoma (on...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1701132

    authors: Mandanas RA,Saez RA,Epstein RB,Confer DL,Selby GB

    更新日期:1998-03-01 00:00:00

  • What would Karl Landsteiner do? The ABO blood group and stem cell transplantation.

    abstract::ABO blood group antigens, of great importance in transplantation and transfusion, are present on virtually all cells, as well as in soluble form in plasma and body fluids. Naturally occurring plasma IgM and IgG antibodies against these antigens are ubiquitous. Nonetheless, the ABO blood group system is widely ignored ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/sj.bmt.1705101

    authors: Heal JM,Liesveld JL,Phillips GL,Blumberg N

    更新日期:2005-11-01 00:00:00

  • Improved immune recovery after transplantation of TCRαβ/CD19-depleted allografts from haploidentical donors in pediatric patients.

    abstract::Immune recovery was retrospectively analyzed in a cohort of 41 patients with acute leukemia, myelodysplastic syndrome and nonmalignant diseases, who received αβ T- and B-cell-depleted allografts from haploidentical family donors. Conditioning regimens consisted of fludarabine or clofarabine, thiotepa, melphalan and se...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2015.87

    authors: Lang P,Feuchtinger T,Teltschik HM,Schwinger W,Schlegel P,Pfeiffer M,Schumm M,Lang AM,Lang B,Schwarze CP,Ebinger M,Urban C,Handgretinger R

    更新日期:2015-06-01 00:00:00

  • 'Real-life' report on the management of chronic GvHD in the Gruppo Italiano Trapianto Midollo Osseo (GITMO).

    abstract::Several guidelines have been published about management of chronic GvHD (cGvHD), but the clinical practice still remains demanding. The Gruppo Italiano Trapianto di Midollo Osseo (GITMO) has planned a prospective observational study on cGvHD, supported by a dedicated software, including the updated recommendations. In...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.223

    authors: Giaccone L,Mancini G,Mordini N,Gargiulo G,De Cecco V,Angelini S,Arpinati M,Baronciani D,Bozzoli V,Bramanti S,Calore E,Cavattoni IM,Cimminiello M,Colombo AA,Facchini L,Falcioni S,Faraci M,Fedele R,Guidi S,Iori AP,M

    更新日期:2018-01-01 00:00:00

  • Neurologic complications after allogeneic hematopoietic stem cell transplantation: risk factors and impact.

    abstract::Neurologic complications (NCs) may be a significant source of morbidity and mortality after hematopoietic cell transplantation (HCT). We performed a retrospective study of 263 consecutive patients undergoing allogeneic HCT for hematological malignancies to determine the incidence, risk factors and clinical impact of N...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/bmt.2017.239

    authors: Dowling MR,Li S,Dey BR,McAfee SL,Hock HR,Spitzer TR,Chen YB,Ballen KK

    更新日期:2018-02-01 00:00:00

  • Evaluation of clinical scale CD34+ cell purification: experience of 71 immunoaffinity column procedures.

    abstract::Seventy-one mobilised PBSC collections were subject to CD34+ cell purification using the CEPRATE SC stem cell concentration system. The overall median purity of CD34+ cells was 69% (6-93%). CD34+ cell, and GM-CFC recoveries were 52% (8-107%) and 36% (3-118%). Purity was logarithmically related to the input percentage ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1700879

    authors: Watts MJ,Sullivan AM,Ings SJ,Leverett D,Peniket AJ,Perry AR,Williams CD,Devereux S,Goldstone AH,Linch DC

    更新日期:1997-07-01 00:00:00

  • Autotransplantation for relapsed or refractory Hodgkin's disease: long-term follow-up and analysis of prognostic factors.

    abstract::Seventy consecutive patients with refractory or relapsed Hodgkin's disease who received high-dose chemotherapy followed by autologous stem cell rescue were analyzed to identify clinically relevant predictors of long-term event-free survival. High-dose therapy consisted primarily of carmustine (BCNU), etoposide, cytara...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1701325

    authors: Lancet JE,Rapoport AP,Brasacchio R,Eberly S,Raubertas RF,Linder T,Muhs A,Duerst RE,Abboud CN,Packman CH,DiPersio JF,Constine LS,Rowe JM,Liesveld JL

    更新日期:1998-08-01 00:00:00

  • Pulmonary hypertension is associated with increased nonrelapse mortality after allogeneic hematopoietic cell transplantation for myelofibrosis.

    abstract::Allogeneic hematopoietic cell transplantation (alloHCT) is the only curative therapy for primary myelofibrosis (MF) as well as myelofibrosis secondary to other myeloproliferative neoplasms (MPN). Pulmonary hypertension (PH) is a known complication of MF and may occur in up to 50% of such patients. PH (defined as a mea...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/s41409-019-0741-8

    authors: Gupta R,Jamal F,Yang D,Chendri C,Aldoss I,Malki MA,Mei M,Salhotra A,Dobrin S,Tran M,Venkataraman K,Palmer J,Stein AS,Sandhu K,Khaled S,Aribi A,Marcucci G,Forman SJ,Snyder D,Nakamura R,Ali H,Pullarkat V

    更新日期:2020-05-01 00:00:00

  • Minimal residual disease testing after stem cell transplantation for multiple myeloma.

    abstract::Increased use of novel agents and autologous stem cell transplantation has led to a significant improvement in PFS and overall survival in patients with multiple myeloma. Despite improved treatment strategies, most patients eventually relapse due to persistent low levels of disease in the bone marrow. Increasingly sen...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章,评审

    doi:10.1038/bmt.2015.164

    authors: Sherrod AM,Hari P,Mosse CA,Walker RC,Cornell RF

    更新日期:2016-01-01 00:00:00

  • The psychosocial impact of haematopoietic SCT on sibling donors.

    abstract::The physical and psychosocial consequences for patients undergoing blood SCT for the treatment of cancer and their families have been extensively documented. There has, however, been far less investigation into the psychosocial consequences for sibling donors who are both family members and undergoing an invasive medi...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/bmt.2012.22

    authors: Pillay B,Lee SJ,Katona L,De Bono S,Warren N,Fletcher J,Burney S

    更新日期:2012-10-01 00:00:00

  • Allogeneic hematopoietic cell transplantation for metastatic breast cancer.

    abstract::We reviewed 66 women with poor-risk metastatic breast cancer from 15 centers to describe the efficacy of allogeneic hematopoietic cell transplantation (HCT). Median follow-up for survivors was 40 months (range, 3-64). A total of 39 patients (59%) received myeloablative and 27 (41%) reduced-intensity conditioning (RIC)...

    journal_title:Bone marrow transplantation

    pub_type: 临床试验,杂志文章

    doi:10.1038/sj.bmt.1705940

    authors: Ueno NT,Rizzo JD,Demirer T,Cheng YC,Hegenbart U,Zhang MJ,Bregni M,Carella A,Blaise D,Bashey A,Bitran JD,Bolwell BJ,Elfenbein GJ,Fields KK,Freytes CO,Gale RP,Lazarus HM,Champlin RE,Stiff PJ,Niederwieser D

    更新日期:2008-03-01 00:00:00

  • Sputum induction as an aid to diagnosis of active cytomegalovirus infection following bone marrow transplantation.

    abstract::An 8-year-old boy received an allogeneic bone marrow transplant (BMT) for relapsed T cell acute lymphoblastic leukaemia. Because he was seropositive for cytomegalovirus (CMV), serial virological specimens were taken throughout the transplant period, and included those obtained by sputum induction. Sixty-one days follo...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:

    authors: Foot AB,Caul EO,Roome AP,Cornish JM,Catterall JR

    更新日期:1990-04-01 00:00:00

  • Prevention of autoimmune hearing loss in MRL/lpr mice by bone marrow transplantation.

    abstract::We examined the effects of bone marrow transplantation (BMT) on immune-mediated inner ear diseases in MRL/Mp-lpr/lpr (MRL/lpr) mice, which manifest not only lupus nephritis but also sensorineural hearing loss (SNHL) at the age of 20 weeks. These mice were treated with cyclophosphamide (CY) and irradiation (5 Gy x 2), ...

    journal_title:Bone marrow transplantation

    pub_type: 杂志文章

    doi:10.1038/sj.bmt.1702636

    authors: Lee S,Iwai H,Sugiura K,Takeuchi K,Kushida T,Tomoda K,Inaba M,Yamashita T,Ikehara S

    更新日期:2000-10-01 00:00:00